New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
Heart failure with reduced ejection fraction (HFrEF) is a public health issue, because some patients, despite using standard treatment, still develop worsening heart failure. The risk of adverse outcomes is especially high in patients who require readmission or emergency care on an outpatient basis....
Saved in:
| Main Author: | I. V. Gribkova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2024-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2954 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01) -
Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study
by: Yinge Zhan, et al.
Published: (2025-02-01) -
Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
by: Alberto Esteban-Fernández, et al.
Published: (2025-01-01) -
Clinical Effectiveness and Safety of Vericiguat in Worsening Heart Failure with Reduced Ejection Fraction: A Single-center, Retrospective Analysis in Indian Patients
by: Pankaj Jariwala, et al.
Published: (2025-01-01) -
Clinical management of heart failure with improved ejection fraction: treatment and maintenance
by: XU Tianyun, et al.
Published: (2025-04-01)